Does intramyocardial injection of M2 macrophage-derived small extracellular vesicles improve cardiac repair in animal models of ischemia-reperfusion injury?
M2 macrophage-derived small extracellular vesicles improve post-AMI cardiac repair and function by regulating pro-inflammatory CCR2+ macrophages via miR-181b-5p, suggesting a potential cell-free therapy for AMI.
Abstract Tissue‐resident cardiac macrophage subsets mediate cardiac tissue inflammation and repair after acute myocardial infarction (AMI). CC chemokine receptor 2 (CCR2)‐expressing macrophages have phenotypical similarities to M1‐polarized macrophages, are pro‐inflammatory, and recruit CCR2 + circulating monocytes to infarcted myocardium. Small extracellular vesicles (sEV) from CCR2 ̶ macrophages, which phenotypically resemble M2‐polarized macrophages, promote anti‐inflammatory activity and cardiac repair. Here, the authors harvested M2 macrophage‐derived sEV (M2 EV ) from M2‐polarized bone‐marrow‐derived macrophages for intramyocardial injection and recapitulation of sEV‐mediated anti‐inflammatory activity in ischemic‐reperfusion (I/R) injured hearts. Rats and pigs received sham surgery; I/R without treatment; or I/R with autologous M2 EV treatment. M2 EV rescued cardiac function and attenuated injury markers, infarct size, and scar size. M2 EV inhibited CCR2 + macrophage numbers, reduced monocyte‐derived CCR2 + macrophage recruitment to infarct sites, induced M1‐to‐M2 macrophage switching and promoted neovascularization. Analysis of M2 EV microRNA content revealed abundant miR‐181b‐5p, which regulated macrophage glucose uptake, glycolysis, and mitigated mitochondrial reactive oxygen species generation. Functional blockade of miR‐181b‐5p is detrimental to beneficial M2 EV actions and resulted in failure to inhibit CCR2 + macrophage numbers and infarct size. Taken together, this investigation showed that M2 EV rescued myocardial function, improved myocardial repair, and regulated CCR2 + macrophages via miR‐181b‐5p‐dependent mechanisms, indicating an option for cell‐free therapy for AMI.
Li et al. (Wed,) studied this question.